Treatment of central nervous system infections caused by Pseudomonas aeruginosa with difficult-to-treat resistance: a narrative review
Abstract
Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-PA) refers to Pseudomonas aeruginosa that is non-susceptible to all first-line antimicrobial agents. With limited therapeutic options available, it poses a severe challenge to anti-infective therapy. For central nervous system infections caused by DTR-PA (DTR-PA-CNSI), the selection of antimicrobial agents is further restricted due to the presence of the blood-brain barrier. The continuous emergence of novel antimicrobial agents, especially new β-lactam antimicrobials, has provided more therapeutic alternatives for DTR-PA infections. This paper mainly discusses the pharmacokinetic/pharmacodynamic studies and clinical research of traditional antimicrobial agents (ceftolozane-tazobactam, ceftazidime-avibactam, aztreonam-avibactam, and cefiderocol) and novel antimicrobial agents (aminoglycosides, polymyxins, and fosfomycin) in the treatment of DTR-PA-CNSI, to evaluate their feasibility and the selection of therapeutic regimens for DTR-PA-CNSI and provide new strategies for clinical medication.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.